Chinese drugmakers pushed towards drugs for new COVID-19 variants | Healthcare Asia Magazine
, China

Chinese drugmakers pushed towards drugs for new COVID-19 variants

Some 19 COVID-19 drugs are in various phases of clinical development in the country.

The resurgence of COVID-19 in China caused by two new Omicron sub-variants has pushed the country to reinforce the emphasis on its zero-COVID policy while companies focus on creating COVID-19 drugs for new variants, according to a report from GlobalData.

GlobalData noted that there are 19 drugs in various phases of clinical development for the treatment of COVID-19 in China. Of these, five drugs are in the Phase III stage. Most of these drugs are targeting various subtypes of COVID-19 variants such as Delta and Omicron.

Anupama Mishra, pharma analyst at GlobalData, said the Omicron variant's sister lineages BA.5 and BA.2 have shown a rise in prevalence and have already spread across at least 25 countries, and these have been designated by the World Health Organization (WHO) as a ‘variant of concern lineage under monitoring’.

READ MORE: China’s pivot to domestic medical devices market could discourage MNCs: report

Currently, there are only two COVID-19 antiviral drugs marketed in the country.

“Owing to the rise in COVID-19 cases in China, there will be demand for more antiviral therapies in future, potentially leading to limited supply. In the wake of rising demand, it is important to accelerate clinical development pathway against these variants to allow more access to effective therapies in China,” Mishra said.

According to GlobalData, as of 4 November, China had 2.93 million confirmed cases and 15,605 deaths due to COVID-19.

The companies developing COVID-19 drugs in China are preparing themselves to target the emerging variants, the report stated. Notably, six drug candidates developed by Chinese manufacturers are in late-stage clinical trials, which are targeting Omicron.

As new COVID-19 variants continue to resurge; it becomes very important for Chinese pharmaceutical companies to align their clinical research towards these variants, Mishra said.

“The pharmaceutical companies with potential efficacy against the rising new Omicron variants can have a potential competitive edge amidst the growing concerns of zero-COVID policy in China,” she said.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!


CHI accelerates the development and adoption of health tech firm innovations
The Centre for Healthcare Innovation invests $2.4m (US1.8m) to set a framework that can test the safety of market-ready innovations.
Catholic Medical Center trailblazing big data and AI adoption in Korean healthcare
Its flagship Seoul St. Mary’s Hospital leads the seamless integration of cutting-edge technology across CMC’s eight affiliate hospitals.
OUE Healthcare poised to capture foreign patient demand for specialist care services
The healthcare group recently partnered with three medical specialist groups including two leading respiratory and cardiothoracic surgery specialist practices.
iClaim boosts Thailand’s health insurance claims in 10 seconds
IT expert Piyawat Maneenual sets up a game-changing platform that allows data transfer from hospitals to insurance companies in real-time.